AXQ Capital
RLMD icon

AXQ Capital’s Relmada Therapeutics RLMD Stock Holding History

AXQ Capital’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-12,093
Closed -$83.7K – 1383
2026
Q2 		$83.7K Buy
+12,093
New +$84.5K 0.01% 864
2023
Q1 		– Sell
-12,483
Closed -$43.6K – 617
2022
Q4 		$43.6K Buy
+12,483
New +$110K 0.03% 311

Other funds holding RLMD

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Spruce Street Capital
Spruce Street Capital New York $629M AUM 210.46% 1-Year Est. Return
JHC
Jones Hill Capital New York $589M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

AXQ Capital's RLMD Position: Q3 2026 in Review

AXQ Capital sold out of Relmada Therapeutics (RLMD) in Q3 2026, closing a stake of 12,093 shares — an estimated $83.7K sold.

AXQ Capital first reported a position in RLMD in Q4 2022 and held it in 2 quarters. The position peaked at $83.7K in Q2 2026. 81 funds tracked by Wall St. Rank hold RLMD as of Q3 2026.

  • AXQ Capital reported no remaining Relmada Therapeutics position as of Q3 2026 after selling out during the quarter.
  • AXQ Capital sold 12,093 Relmada Therapeutics shares in Q3 2026, an estimated $83.7K.
  • AXQ Capital first reported a position in Relmada Therapeutics in Q4 2022 and held it in 2 quarters.
  • AXQ Capital's Relmada Therapeutics position peaked at $83.7K in Q2 2026.
  • 81 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2026.

Based on AXQ Capital's 13F filing for Q3 2026, filed 12 Nov 2026.